Shots: The approval is based on P-III KEYNOTE-048 study results assessing Keytruda as monothx. & in combination with platinum and fluorouracil (FU) vs EXTREME regimen in 882 patients in ratio […]readmore
Tags : Recurrent
Shots: The P-III KEYNOTE-048 study results involves assessing of Keytruda + CT (carboplatin/cisplatin + 5-FU) and Keytruda as monothx. vs EXTREME regimen in 882 patients with recurrent or metastatic HNSCC, […]readmore
Shots: Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and […]readmore
Shots: The P-III ATTRACTION-3 study involves assessing of Opdivo (involumab, IV) vs CT (docetaxel/paclitaxel) in patients with unresectable advanced or recurrent esophageal cancer or intolerant to fluoropyrimidine + PT-based drug […]readmore